The End of the Cheap Patient

For more than a decade, Turkish health tourism rested on a single value proposition: the same treatment available in Western Europe, at half the cost. It proved remarkably effective, building a sector that served nearly 1.4 million international patients in 2025 and generated over $3 billion in revenue. The first-quarter figures for 2026, however, suggest that this model has reached its limit.

According to data released in July by the Turkish Exporters' Assembly's service export body (HİB), Turkey treated 302,487 international patients in the first three months of the year, earning $761.5 million. For a sector accustomed to growth headlines, the topline is unremarkable. What stands out is that revenue per patient rose roughly 39% year on year — far outpacing patient volume, and indicating that the sector is now generating value rather than merely scale. Behind that shift lies a marked change in who the patient is.

A different patient

A detail in the HİB statement clarifies the nature of this change. In advanced treatment categories — oncology, robotic surgery, organ transplantation, cardiovascular surgery — per-patient spending runs between $10,000 and $50,000. The revenue gains are not being driven by higher volumes of cosmetic procedures or hair transplants, but by a new cohort choosing Turkey for high-risk, high-cost care.

This cohort makes decisions in a structurally different way. In elective, low-risk procedures, price comparison is decisive. In complex treatment, the patient's central questions concern outcomes rather than cost: how complications would be managed, what mechanism audits the institution's clinical standards, and how follow-up care will be arranged after the return home.

The patient experience literature describes well what happens when these questions go unanswered. The patient does not object or negotiate; they quietly withdraw from the conversation. Clinic management typically records such losses as price objections. What has actually failed is not price competitiveness but trust communication — and in a market where per-patient revenue is climbing, the inability to make that distinction means systematically losing the most valuable segment.

The regulatory threshold

This market transformation is running in parallel with a regulatory one. Under the Regulation on International Health Tourism, published in April 2025, all facilities holding a health tourism authorisation certificate must complete accreditation through TÜSKA, Turkey's national health quality and accreditation institute, by 31 December 2026. TÜSKA has stated unambiguously that facilities failing to meet the deadline will no longer be permitted to admit international patients. The regulation additionally mandates registration on the state-run HealthTürkiye portal and complication insurance for surgical procedures.

Within the sector, this timetable is discussed largely as a compliance burden, and given the audit processes, certification costs and insurance premiums involved, the characterisation is not unfair. What it misses is the strategic dimension. Accreditation, complication insurance and state-supervised registration are the institutional counterparts of precisely those questions the high-value patient needs answered before committing. The regulator, in effect, has made mandatory the trust infrastructure the market was already demanding.

Seen in this light, the December deadline will function as a sorting mechanism. Facilities that fail to clear the threshold will exit the market; among those that clear it, competition will shift from possessing the certificate to communicating it. The distance between an institution that files its accreditation away and one that places it at the centre of its international communications is likely to be among the defining features of the sector's next competitive phase.

The role of the incentive framework

The third element of the picture is Presidential Decision No. 10962, published at the end of February, which consolidated Turkey's service export supports under a single instrument. As reported, the decision sets a base support rate of 50%, with additional points for activity directed at designated target countries. In practice, this means that a substantial share of promotion and marketing expenditure aimed at priority markets can be met from public funds, provided the documentation is prepared to standard.

Read together, the three developments form a coherent policy framework: the market rewards trust-based positioning, the regulation makes its minimum conditions compulsory, and the incentive system finances its communication abroad. Despite this alignment, a significant portion of the sector's marketing practice continues to operate on the old model of circulating price lists.

Conclusion

The 39% rise in per-patient revenue can reasonably be read as the first concrete indicator of Turkish health tourism's departure from its identity as a low-cost destination. For the sector, this transition represents maturation rather than loss — but it will not complete itself. The language of price competition and the language of trust competition are different languages, and the accreditation deadline expiring in December marks the end of the period in which choosing between them could be deferred.

Sources: Turkish Exporters' Assembly (HİB) Q1 2026 health services figures (July 2026); USHAŞ 2025 sector data; TÜSKA accreditation notices; Regulation on International Health Tourism and Tourist Health (Official Gazette, 26 April 2025); Decision No. 10962 (Official Gazette, 27 February 2026). Support rates should be verified against the Official Gazette text prior to publication.